Selected article for: "death risk and respiratory distress syndrome"

Author: Toapanta, Néstor; Torres, Irina B; Sellarés, Joana; Chamoun, Betty; Serón, Daniel; Moreso, Francesc
Title: Kidney transplantation and COVID-19 renal and patient prognosis
  • Cord-id: lsqnbdvu
  • Document date: 2021_3_26
  • ID: lsqnbdvu
    Snippet: Coronavirus disease 2019 (COVD-19) emerged as a pandemic in December 2019. Infection has spread quickly and renal transplant recipients receiving chronic immunosuppression have been considered a population at high risk of infection, complications and infection-related death. During this year a large amount of information from nationwide registries, multicentre and single-centre studies have been reported. The number of renal transplant patients diagnosed with COVID-19 was higher than in the gene
    Document: Coronavirus disease 2019 (COVD-19) emerged as a pandemic in December 2019. Infection has spread quickly and renal transplant recipients receiving chronic immunosuppression have been considered a population at high risk of infection, complications and infection-related death. During this year a large amount of information from nationwide registries, multicentre and single-centre studies have been reported. The number of renal transplant patients diagnosed with COVID-19 was higher than in the general population, but the lower threshold for testing may have contributed to its better identification. Major complications such as acute kidney injury and acute respiratory distress syndrome were very frequent in renal transplant patients, with a high comorbidity burden, but further studies are needed to support that organ transplant recipients receiving chronic immunosuppression are more prone to develop these complications than the general population. Kidney transplant recipients experience a high mortality rate compared with the general population, especially during the very early post-transplant period. Despite the fact that some studies report more favourable outcomes in patients with a kidney transplant than in patients on the kidney waiting list, the higher mortality described in the very early post-transplant period would advise against performing a kidney transplant in areas where the spread of infection is high, especially in recipients >60 years of age. Management of transplant recipients has been challenging for clinicians and strategies such as less use of lymphocyte-depleting agents for new transplants or anti-metabolite withdrawal and calcineurin inhibitor reduction for transplant patients with COVID-19 are not based on high-quality evidence.

    Search related documents:
    Co phrase search for related documents
    • absolute lymphocyte count and lopinavir ritonavir: 1
    • absolute lymphocyte count and low incidence: 1
    • absolute lymphocyte count and low lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • absolute lymphocyte count and lung disease: 1, 2, 3, 4, 5
    • absolute lymphocyte count and lung function: 1, 2, 3, 4
    • absolute lymphocyte count and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • activity reduce and acute aki kidney injury: 1
    • activity reduce and acute rejection: 1
    • activity reduce and long period: 1
    • activity reduce and low quality: 1, 2
    • activity reduce and low threshold: 1
    • activity reduce and lung disease: 1, 2
    • acute aki kidney injury and additional risk: 1, 2, 3, 4, 5, 6, 7
    • acute aki kidney injury and admission race: 1
    • acute aki kidney injury and admission race age: 1
    • acute aki kidney injury and long period: 1, 2
    • acute aki kidney injury and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8
    • acute aki kidney injury and lopinavir ritonavir hydroxychloroquine: 1, 2
    • acute aki kidney injury and low incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11